CFM
PROK icon

Catalyst Funds Management’s ProKidney PROK Stock Holding History

Catalyst Funds Management’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-47,800
Closed -$85.6K – 835
2026
Q1 		$85.6K Buy
+47,800
New +$101K 0.01% 501
2025
Q3 		– Sell
-61,100
Closed -$36.2K – 618
2025
Q2 		$36.2K Buy
+61,100
New +$47.6K 0.01% 393

Other funds holding PROK

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $542M AUM 206.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Catalyst Funds Management's PROK Position: Q2 2026 in Review

Catalyst Funds Management sold out of ProKidney (PROK) in Q2 2026, closing a stake of 47,800 shares — an estimated $85.6K sold.

Catalyst Funds Management first reported a position in PROK in Q2 2025 and held it in 2 quarters. The position peaked at $85.6K in Q1 2026. 71 funds tracked by Wall St. Rank hold PROK as of Q2 2026.

  • Catalyst Funds Management reported no remaining ProKidney position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 47,800 ProKidney shares in Q2 2026, an estimated $85.6K.
  • Catalyst Funds Management first reported a position in ProKidney in Q2 2025 and held it in 2 quarters.
  • Catalyst Funds Management's ProKidney position peaked at $85.6K in Q1 2026.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.